Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma

Journal of Cellular Biochemistry

Volumn 116, Issue 11, 2015, Pages 2465-2475

  Guo, Yan ^a,b   Pan, Qiao ^b   Zhang, Jing ^a   Xu, Xinyuan ^a   Liu, Xiping ^a   Wang, Qinhao ^a   Yi, Ru ^a   Xie, Xiaobo ^c   Yao, Libo ^b   Liu, Wenchao ^b   Shen, Lan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Cardiology Xijing Hospital Fourth Military Medical University ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE TAZ; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SURVIVAL TIME; TUMOR VOLUME; AGED; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; ONCOGENES; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84941028546     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25117     Document Type: Article

References (43)

1. Basu S, Totty NF, Irwin MS, Sudol M, Downward J., 2003. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11: 11-23.
2. Block T, Mehta AS, London WT., 2010. Hepatocellular carcinoma of the liver. Cancer Biomark 9: 375-383.
3. Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W., 2011. The Hippo pathway in biological control and cancer development. J Cell Physiol 226: 928-939.
4. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W., 2009. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 284: 14347-14358.
5. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT., 2005. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280: 41553-41561.
6. Chu CY, Chang CC, Prakash E, Kuo ML., 2008. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 15: 675-685.
7. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S., 2011. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147: 759-772.
8. Cui JF, Liu YK, Zhang LJ, Shen HL, Song HY, Dai Z, Yu YL, Zhang Y, Sun RX, Chen J, Tang ZY, Yang PY., 2006. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 6: 5953-5961.
9. de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, Fusco A, Zannini M., 2011. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer 47: 926-933.
10. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D., 2007. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133.
11. Guo P, Zhao KW, Dong XY, Sun X, Dong JT., 2009. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. J Biol Chem 284: 18184-18193.
12. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB., 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309: 1074-1078.
13. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W., 2007. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci USA 104: 1631-1636.
14. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB., 2000. TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19: 6778-6791.
15. Kudo M., 2011. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 81 (Suppl 1): 50-55.
16. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL., 2008. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28: 2426-2436.
17. Lencioni R, Crocetti L., 2012. Local-regional treatment of hepatocellular carcinoma. Radiology 262: 43-58.
18. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S, Guan KL., 2010. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 24: 1106-1118.
19. Liu AM, Poon RT, Luk JM., 2010a MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 394: 623-627.
20. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM., 2010b Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 14: 855-868.
21. Luk JM, Liu AM., 2011. Proteomics of hepatocellular carcinoma in Chinese patients. OMICS 15: 261-266.
22. Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T, Mitani A, Nagase T, Yatomi Y, Aburatani H, Nakagawa O, Small EV, Cobo-Stark P, Igarashi P, Murakami M, Tominaga J, Sato T, Asano T, Kurihara Y, Kurihara H., 2008. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 294: F542-553.
23. Masuda T, Miyoshi E., 2011. Cancer biomarkers for hepatocellular carcinomas: From traditional markers to recent topics. Clin Chem Lab Med 49: 959-966.
24. McConnell BB, Bialkowska AB, Nandan MO, Ghaleb AM, Gordon FJ, Yang VW., 2009. Haploinsufficiency of Kruppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res 69: 4125-4133.
25. Murakami M, Nakagawa M, Olson EN, Nakagawa O., 2005. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA 102: 18034-18039.
26. Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, Asano T, Kurihara H., 2006. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun 339: 533-539.
27. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA., 2006. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103: 12405-12410.
28. Pan D., 2010. The hippo signaling pathway in development and cancer. Dev Cell 19: 491-505.
29. Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP., 2007. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood 109: 3080-3083.
30. Shi H, Li N, Li S, Chen C, Wang W, Xu C, Zhang J, Jin H, Zhang H, Zhao H, Song W, Feng Q, Feng X, Shen X, Yao L, Zhao Q., 2010. Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci 101: 1292-1299.
31. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA., 2008. Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589.
32. Tanaka S, Arii S., 2011. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol 46: 289-296.
33. Usui S, Sugimoto N, Takuwa N, Sakagami S, Takata S, Kaneko S, Takuwa Y., 2004. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem 279: 12300-12311.
34. Washburn K, Halff G., 2011. Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant 16: 297-300.
35. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM., 2009. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
36. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ, Basu S., 2008. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15: 1752-1759.
37. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW., 2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267.
38. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL., 2009. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 284: 13355-13362.
39. Zhao B, Li L, Lei Q, Guan KL., 2010. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 24: 862-874.
40. Zhao D, Zhi X, Zhou Z, Chen C., 2012. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 33: 59-67.
41. Zheng HQ, Zhou Z, Huang J, Chaudhury L, Dong JT, Chen C., 2009. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene 28: 3702-3713.
42. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM., 2008. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85: 1726-1732.
43. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X., 2011. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30: 2181-2186.